The efficacy of prophylactic azithromycin on bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation

International Journal of Hematology

Volumn 102, Issue 3, 2015, Pages 357-363

  Jo, Kyung Wook ^a   Yoon, Shinkyo ^b   Song, Jin Woo ^a   Shim, Tae Sun ^a   Lee, Sei Won ^a   Lee, Jae Seung ^a   Kim, Dae Young ^a   Lee, Je Hwan ^a   Lee, Jung Hee ^a   Choi, Yunsuk ^a   Lee, Kyoo Hyung ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Kyungpook National University School of Medicine   (South Korea)

Author keywords

Azithromycin; Bronchiolitis obliterans syndrome; Hematopoietic stem cell transplantation; Prophylaxis

Indexed keywords

AZITHROMYCIN; BUSULFAN;

ACUTE LEUKEMIA; ADULT; ARTICLE; BRONCHIOLITIS OBLITERANS; BRONCHIOLITIS OBLITERANS SYNDROME; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTOR VARIABLE; PROPHYLAXIS; RETROSPECTIVE STUDY; SOUTH KOREA; TERTIARY CARE CENTER; ADOLESCENT; AGED; ALLOGRAFT; CLINICAL TRIAL; HEMATOLOGIC DISEASES; IMMUNOSUPPRESSIVE TREATMENT; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; ALLOGRAFTS; AZITHROMYCIN; BRONCHIOLITIS OBLITERANS; FEMALE; FOLLOW-UP STUDIES; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING;

EID: 84941259687     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-015-1830-0     Document Type: Article

References (24)

1. Chi AK, Soubani AO, White AC, Miller KB. An update on pulmonary complications of hematopoietic stem cell transplantation. Chest. 2013;144:1913–22.
2. Uhlving HH, Buchvald F, Heilmann CJ, Nielsen KG, Gormsen M. Müller KG Bronchiolitis obliterans after allo-SCT: clinical criteria and treatment options. Bone Marrow Transplant. 2012;47:1020–9.
3. Chien JW, Duncan S, Williams KM, Pavletic SZ. Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation-an increasingly recognized manifestation of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2010;16:S106–14.
4. Barker AF, Bergeron A, Rom WN, Hertz MI. Obliterative bronchiolitis. N Engl J Med. 2014;370:1820–8.
5. Todd JL, Palmer SM. Bronchiolitis obliterans syndrome: the final frontier for lung transplantation. Chest. 2011;140:502–8.
6. Santo Tomas LH, Loberiza FR Jr, Klein JP, Layde PM, Lipchik RJ, Rizzo JD, et al. Risk factors for bronchiolitis obliterans in allogeneic hematopoietic stem-cell transplantation for leukemia. Chest. 2005;128:153–61.
7. Yusen RD, Christie JD, Edwards LB, Kucheryavaya AY, Benden C, Dipchand AI, et al. The Registry of the International Society for Heart and Lung Transplantation: thirtieth Adult Lung and Heart-Lung Transplant Report–2013; focus theme: age. J Heart Lung Transplant. 2013;32:965–78.
8. Dudek AZ, Mahaseth H, DeFor TE, Weisdorf DJ. Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes. Biol Blood Marrow Transplant. 2003;9:657–66.
9. Or R, Gesundheit B, Resnick I, Bitan M, Avraham A, Avgil M, et al. Sparing effect by montelukast treatment for chronic graft versus host disease: a pilot study. Transplantation. 2007;83:577–81.
10. Bergeron A, Belle A, Chevret S, Ribaud P, Devergie A, Esperou H, et al. Combined inhaled steroids and bronchodilatators in obstructive airway disease after allogeneic stem cell transplantation. Bone Marrow Transplant. 2007;39:547–53.
11. Lam DC, Lam B, Wong MK, Lu C, Au WY, Tse EW, et al. Effects of azithromycin in bronchiolitis obliterans syndrome after hematopoietic SCT–a randomized double-blinded placebo-controlled study. Bone Marrow Transplant. 2011;46:1551–6.
12. Vos R, Vanaudenaerde BM, Verleden SE, De Vleeschauwer SI, Willems-Widyastuti A, Van Raemdonck DE, et al. A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation. Eur Respir J. 2011;37:164–72.
13. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11:945–56.
14. Nakasone H, Kanda J, Yano S, Atsuta Y, Ago H, Fukuda T, et al. A case-control study of bronchiolitis obliterans syndrome following allogeneic hematopoietic stem cell transplantation. Transpl Int. 2013;26:631–9.
15. Gazourian L, Rogers AJ, Ibanga R, Weinhouse GL, Pinto-Plata V, Ritz J, et al. Factors associated with bronchiolitis obliterans syndrome and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation. Am J Hematol. 2014;89:404–9.
16. Gottlieb J, Szangolies J, Koehnlein T, Golpon H, Simon A, Welte T. Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation. Transplantation. 2008;85:36–41.
17. Verleden GM, Vanaudenaerde BM, Dupont LJ, Van Raemdonck DE. Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med. 2006;174:566–70.
18. Verleden GM, Raghu G, Meyer KC, Glanville AR, Corris P. A new classification system for chronic lung allograft dysfunction. J Heart Lung Transplant. 2014;33:127–33.
19. Khalid M, Al Saghir A, Saleemi S, Al Dammas S, Zeitouni M, Al Mobeireek A, et al. Azithromycin in bronchiolitis obliterans complicating bone marrow transplantation: a preliminary study. Eur Respir J. 2005;25:490–3.
20. Verleden GM, Vos R, Dupont L, Van Raemdonck DE, Vanaudenaerde BM, Verleden SE. Are we near to an effective drug treatment for bronchiolitis obliterans? Expert Opin Pharmacother. 2014;15:2117–20.
21. Verleden GM, Verleden SE, Vos R, De Vleeschauwer SI, Dupont LJ, Van Raemdonck DE, et al. Montelukast for bronchiolitis obliterans syndrome after lung transplantation: a pilot study. Transpl Int. 2011;24:651–6.
22. Estenne M, Maurer JR, Boehler A, Egan JJ, Frost A, Hertz M, et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant. 2002;21:297–310.
23. Goers TA, Ramachandran S, Aloush A, Trulock E, Patterson GA, Mohanakumar T. De novo production of K-alpha1 tubulin-specific antibodies: role in chronic lung allograft rejection. J Immunol. 2008;180:4487–94.
24. Berry G, Burke M, Andersen C, Angelini A, Bruneval P, Calabrese F, et al. Pathology of pulmonary antibody-mediated rejection: 2012 update from the Pathology Council of the ISHLT. J Heart Lung Transplant. 2013;32:14–21.